AAP
MXCT icon

Arax Advisory Partners’s MaxCyte MXCT Stock Holding History

Arax Advisory Partners’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$308 Buy
+227
New +$212 ﹤0.01% 3486
2025
Q4 		– Sell
-2,121
Closed -$3.35K – 4375
2025
Q3 		$3.35K Buy
+2,121
New +$3.69K ﹤0.01% 2980

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $88.9M AUM

Arax Advisory Partners's MXCT Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in MaxCyte (MXCT) in Q1 2026: 227 shares worth $308. The stake represents ﹤0.01% of the portfolio and ranks #3486 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in MXCT as recently as Q3 2025.

Arax Advisory Partners first reported a position in MXCT in Q3 2025 and has held it in 2 quarters since. The position peaked at $3.35K in Q3 2025. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • Arax Advisory Partners held 227 shares of MaxCyte worth $308 as of Q1 2026.
  • MaxCyte was a new Arax Advisory Partners position in Q1 2026.
  • MaxCyte made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3486 holding.
  • Arax Advisory Partners first reported a position in MaxCyte in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's MaxCyte position peaked at $3.35K in Q3 2025.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.